1 December 2020 - The December 2020 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The December issue of the Schedule includes a few new/revised listings:

• Beclomethasone propionate with eformoterol fumarate dihydrate (Fostair) - new combination product
• Clostridium botulinum toxin type A (Dysport) - new indication
  
• Dolutegravir sodium with lamivudine (Dovato) - new indication
• Ixekizumab (Taltz) - new indication
• Mesalazine (Pentasa) - restriction change
• Nusinersen sodium (Spinraza) - new indication
• Paracetamol (Panadol) - new formulation
• Protein formula with vitamins and minerals low in potassium, phosphorus, calcium, chloride and vitamin A (Renastep) - New combination product
• Rifampicin (Rimycin) - new indication
• Rivaroxaban (Xarelto) - new indication
• Venetoclax (Venclexta) - new indication

Read Summary of Changes